Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention


  Free Subscription

Articles published in Biochem Pharmacol

Retrieve available abstracts of 14 articles:
HTML format

Single Articles

    October 2022
  1. HEGE HURRISH K, Qiao X, Li X, Su Y, et al
    Co-targeting of HDAC, PI3K, and Bcl-2 results in metabolic and transcriptional reprogramming and decreased mitochondrial function in acute myeloid leukemia.
    Biochem Pharmacol. 2022;205:115283.
    PubMed     Abstract available

    June 2022
  2. GUO J, Liu K, Wang J, Jiang H, et al
    A rational foundation for micheliolide-based combination strategy by targeting redox and metabolic circuit in cancer cells.
    Biochem Pharmacol. 2022;200:115037.
    PubMed     Abstract available

    April 2022
  3. GUPTE A, Al-Antary ET, Edwards H, Ravindranath Y, et al
    The Paradox of Myeloid Leukemia Associated with Down Syndrome.
    Biochem Pharmacol. 2022 Apr 25:115046. doi: 10.1016/j.bcp.2022.115046.
    PubMed     Abstract available

  4. ZHANG H, Song T, Wang Z, Laura Bonnette U, et al
    Bcr-Abl drives the formation of Hsp70/Bim PPI to stabilize oncogenic clients and prevent cells from undergoing apoptosis.
    Biochem Pharmacol. 2022;198:114964.
    PubMed     Abstract available

    March 2022
  5. LEE YC, Chiou JT, Wang LJ, Chang LS, et al
    Hydroquinone destabilizes BIM mRNA through upregulation of p62 in chronic myeloid leukemia cells.
    Biochem Pharmacol. 2022;199:115017.
    PubMed     Abstract available

  6. SUN L, Wang J, Wang Q, He Z, et al
    Pretreatment of umbilical cord derived MSCs with IFN-gamma and TNF-alpha enhances the tumor-suppressive effect on acute myeloid leukemia.
    Biochem Pharmacol. 2022;199:115007.
    PubMed     Abstract available

    February 2022
  7. XING GAO Z, Long Cui Z, Ran Zhou M, Fu Y, et al
    The new mitochondrial uncoupler BAM15 induces ROS production for treatment of acute myeloid leukemia.
    Biochem Pharmacol. 2022 Feb 19:114948. doi: 10.1016/j.bcp.2022.114948.
    PubMed     Abstract available

  8. XIN Q, Chen Z, Wei W, Wu Y, et al
    Animal Models of Acute lymphoblastic leukemia: recapitulating the human disease to evaluate drug efficacy and discover therapeutic targets.
    Biochem Pharmacol. 2022 Feb 17:114970. doi: 10.1016/j.bcp.2022.114970.
    PubMed     Abstract available

    October 2021
  9. VIGON L, Martinez-Roman P, Rodriguez-Mora S, Torres M, et al
    Provirus reactivation is impaired in HIV-1 infected individuals on treatment with dasatinib and antiretroviral therapy.
    Biochem Pharmacol. 2021;192:114666.
    PubMed     Abstract available

    July 2021
  10. LU X, Yan G, Dawood M, Klauck SM, et al
    A novel moniliformin derivative as pan-inhibitor of histone deacetylases triggering apoptosis of leukemia cells.
    Biochem Pharmacol. 2021 Jul 12:114677. doi: 10.1016/j.bcp.2021.114677.
    PubMed     Abstract available

    June 2021
  11. KIM JH, Lee SJ, Kang KW, Lee BH, et al
    CXCR2, a novel target to overcome tyrosine kinase inhibitor resistance in chronic myelogenous leukemia cells.
    Biochem Pharmacol. 2021;190:114658.
    PubMed     Abstract available

    April 2021
  12. WANG F, Huang J, Guo T, Zheng Y, et al
    Homoharringtonine synergizes with quizartinib in FLT3-ITD acute myeloid leukemia by targeting FLT3-AKT-c-Myc pathway.
    Biochem Pharmacol. 2021 Apr 5:114538. doi: 10.1016/j.bcp.2021.114538.
    PubMed     Abstract available

  13. CHIOU JT, Lee YC, Huang CH, Wang LJ, et al
    Inhibition of Sp1-mediated survivin and MCL1 expression cooperates with SLC35F2 and myeloperoxidase to modulate YM155 cytotoxicity to human leukemia cells.
    Biochem Pharmacol. 2021 Apr 5:114544. doi: 10.1016/j.bcp.2021.114544.
    PubMed     Abstract available

    January 2021
  14. MARENSI V, Keeshan KR, MacEwan DJ
    Pharmacological impact of FLT3 mutations on receptor activity and responsiveness to tyrosine kinase inhibitors.
    Biochem Pharmacol. 2021;183:114348.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Leukemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.